S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.63 (+0.54%)
AAPL   180.75 (-0.37%)
MSFT   407.88 (+0.04%)
META   487.80 (+0.78%)
GOOGL   137.06 (+0.50%)
AMZN   174.65 (+0.86%)
TSLA   199.87 (-1.07%)
NVDA   791.14 (+1.87%)
NIO   5.64 (+3.87%)
AMD   186.56 (+5.68%)
BABA   74.20 (-0.52%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.53 (-0.20%)
CGC   3.32 (-1.19%)
GE   156.12 (+0.33%)
DIS   111.32 (+0.47%)
AMC   4.43 (-11.22%)
PFE   26.89 (-0.55%)
PYPL   60.71 (+0.76%)
XOM   104.75 (+0.41%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.63 (+0.54%)
AAPL   180.75 (-0.37%)
MSFT   407.88 (+0.04%)
META   487.80 (+0.78%)
GOOGL   137.06 (+0.50%)
AMZN   174.65 (+0.86%)
TSLA   199.87 (-1.07%)
NVDA   791.14 (+1.87%)
NIO   5.64 (+3.87%)
AMD   186.56 (+5.68%)
BABA   74.20 (-0.52%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.53 (-0.20%)
CGC   3.32 (-1.19%)
GE   156.12 (+0.33%)
DIS   111.32 (+0.47%)
AMC   4.43 (-11.22%)
PFE   26.89 (-0.55%)
PYPL   60.71 (+0.76%)
XOM   104.75 (+0.41%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.63 (+0.54%)
AAPL   180.75 (-0.37%)
MSFT   407.88 (+0.04%)
META   487.80 (+0.78%)
GOOGL   137.06 (+0.50%)
AMZN   174.65 (+0.86%)
TSLA   199.87 (-1.07%)
NVDA   791.14 (+1.87%)
NIO   5.64 (+3.87%)
AMD   186.56 (+5.68%)
BABA   74.20 (-0.52%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.53 (-0.20%)
CGC   3.32 (-1.19%)
GE   156.12 (+0.33%)
DIS   111.32 (+0.47%)
AMC   4.43 (-11.22%)
PFE   26.89 (-0.55%)
PYPL   60.71 (+0.76%)
XOM   104.75 (+0.41%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.63 (+0.54%)
AAPL   180.75 (-0.37%)
MSFT   407.88 (+0.04%)
META   487.80 (+0.78%)
GOOGL   137.06 (+0.50%)
AMZN   174.65 (+0.86%)
TSLA   199.87 (-1.07%)
NVDA   791.14 (+1.87%)
NIO   5.64 (+3.87%)
AMD   186.56 (+5.68%)
BABA   74.20 (-0.52%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.53 (-0.20%)
CGC   3.32 (-1.19%)
GE   156.12 (+0.33%)
DIS   111.32 (+0.47%)
AMC   4.43 (-11.22%)
PFE   26.89 (-0.55%)
PYPL   60.71 (+0.76%)
XOM   104.75 (+0.41%)
NASDAQ:DARE

Daré Bioscience (DARE) Stock Price, News & Analysis

$0.54
+0.04 (+7.19%)
(As of 11:08 AM ET)
Today's Range
$0.50
$0.55
50-Day Range
$0.31
$0.54
52-Week Range
$0.27
$1.15
Volume
362,304 shs
Average Volume
447,960 shs
Market Capitalization
$53.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Daré Bioscience MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,090.9% Upside
$6.00 Price Target
Short Interest
Healthy
0.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Daré Bioscience in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.41) to ($0.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

588th out of 958 stocks

Pharmaceutical Preparations Industry

283rd out of 450 stocks


DARE stock logo

About Daré Bioscience Stock (NASDAQ:DARE)

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

DARE Stock Price History

DARE Stock News Headlines

The Press: $1,000 Dare
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Remote learning day for Dare County
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Coastal Flood Watch in Dare County until Feb. 13
Daré Bioscience announces executive team changes
Dare Bioscience to Lose Two Executives, Directors
See More Headlines
Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/29/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DARE
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+1,090.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,950,000.00
Pretax Margin
-4,104.70%

Debt

Sales & Book Value

Annual Sales
$10 million
Book Value
$0.13 per share

Miscellaneous

Free Float
93,338,000
Market Cap
$49.65 million
Optionable
Not Optionable
Beta
1.03
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Ms. Sabrina Martucci Johnson (Age 57)
    CEO, President, Principal Financial Officer, Secretary & Director
    Comp: $804.07k
  • Ms. Lisa Walters-Hoffert (Age 65)
    Executive Officer
    Comp: $523.2k
  • Mr. Mark Walters (Age 69)
    Vice President of Operations
  • Ms. MarDee J. Haring-Layton (Age 48)
    Chief Accounting Officer
  • Dr. David Friend
    Chief Scientific Officer














DARE Stock Analysis - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DARE shares.
View DARE analyst ratings
or view top-rated stocks.

What is Daré Bioscience's stock price target for 2024?

2 equities research analysts have issued 12 month price objectives for Daré Bioscience's stock. Their DARE share price targets range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 1,090.9% from the stock's current price.
View analysts price targets for DARE
or view top-rated stocks among Wall Street analysts.

How have DARE shares performed in 2024?

Daré Bioscience's stock was trading at $0.3090 at the start of the year. Since then, DARE shares have increased by 63.0% and is now trading at $0.5038.
View the best growth stocks for 2024 here
.

When is Daré Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our DARE earnings forecast
.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) posted its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. During the same quarter last year, the business posted ($0.24) EPS.

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

Who are Daré Bioscience's major shareholders?

Daré Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Daré Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DARE) was last updated on 2/29/2024 by MarketBeat.com Staff